



## **Ventripoint Issues Option Grants and Reports Exercise of Options and Warrants**

**Toronto, Ontario – The Newswire – January 21, 2022** - Ventripoint Diagnostics Ltd. (“**Ventripoint**” or the “**Corporation**”)(TSXV:VPT, OTCQB:VPTDF) announces that on January 20, 2022 the Corporation granted an aggregate of 1,725,000 options to directors, officers, employees, contractors and consultants of the Corporation with an exercise price of \$0.40 and with terms from one to ten years and vesting from immediately to over 3 years. Of these option grants, 500,000 were awarded to directors and officers of the Corporation. The Corporation now has 4,096,590 options available for future grants under the Stock Option Plan as approved by shareholders at the last Special and Annual General Meeting on August 9, 2021.

Since the last update (see NR May 6, 2021), a total of 1,770,000 options were exercised with a weighted average price of approximately \$0.22 per share for gross proceeds to the Corporation of \$385,250. There are currently 8,958,750 option grants outstanding with exercise prices between \$0.10 to \$0.50 with a weighted average price of \$0.27, and 5,037,500 of these options have vested.

Since the last update (see NR May 6, 2021), the Corporation has had 1,000,000 of the warrants issued on October 2, 2019 exercised at the strike price of \$0.115 for gross proceeds of \$115,000. There remain 288,666 outstanding warrants in this series, which expire on October 2, 2022.

The Corporation currently has 155,558,905 common shares issued and outstanding.

### **About Ventripoint Diagnostics Ltd.**

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Peter Weichler, Investor Relations

Email: [peter@weichler.ca](mailto:peter@weichler.ca)

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

### **Forward Looking Statements**

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR at [www.sedar.com](http://www.sedar.com). Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.